150 likes | 217 Views
Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body. TT - 2002. SAAVI aims to develop an affordable , effective and locally relevant preventative HIV vaccine for southern Africa. G. G. J. J. AE. G. AE. H. AE. AG. AG. B. B. B. AG. B. B.
E N D
Established in late 1999 • Scientific/clinical resources • Ethics committees • Regulatory body TT - 2002
SAAVIaims to develop anaffordable, effective and locally relevantpreventativeHIV vaccineforsouthern Africa
G G J J AE G AE H AE AG AG B B B AG B B A B A B A A D D C D C D D C C C F C F K C K C C C C C C C C C C HIV genetic diversity C. Williamson et al
Immunology assessment Animal Human Making the vaccine Testing the vaccine Others Advocacy & community Ethical issues TT - 2002
90% Progress to AIDS in 5 years 5% “Viral load” in HIV Amount of HIV
SAAVI Challenges TT - 2002
Immunology assessment Animal Human Making the vaccine Testing the vaccine Others Advocacy & community Ethical issues TT - 2002
Supporters and Funds TT - 2002
Good vaccine candidates • HIV subtypes • Community involvement • Ethical studies • Access to product • Pricing • Technology transfer Appropriate Clinical Trials $30 million TT - 2002
Product? • When? • What dose? • Manufacturing plant • Personnel • Dose price • Distribution capacity Manufacturing • Clinical trials lot • Bulk supply $350 million TT - 2002
Government • Medicines Control Council • Ethics committees • Medical aids • Life Insurance • Blood transfusion services • State Vaccine Institute Strategic national alliances TT - 2002
Strategic international alliances • NIH • HVTN • IAVI • AAVP • EU • Public / private TT - 2002
CONCLUSIONS • SAAVI has dynamic team • Different to all other initiatives • Committed to excellence • Massive / maturing challenges • Consolidate and expand TT - 2002